Hanmi Pharmaceutical Nears Korean Launch for Obesity Drug EPPE After Five-Year Detour
Licensed out to French pharmaceutical giant Sanofi in 2015 and returned five years later, Hanmi Pharmaceutical’s obesity drug candidate "EPPE" has...
Search results for "product approval"
Zymfentra U.S. Sales Surge 176% as Celltrion’s Remsima Franchise Eyes 1 Trillion Won Annual Revenue
Biopharmaceutical company Celltrion announced on Aug. 27 that combined first-half sales of its subcutaneous infliximab products—Remsima SC and...
South Korea Bans Pharmacies From Using 'Warehouse' or 'Factory' on Signage
Pharmacies in South Korea will no longer be allowed to use terms that evoke a “warehouse” or “factory” on their...
Moderna’s Landmark mRNA Cancer Vaccine Phase 3 Success Spotlights Korean Biotech Ties
Positive late-stage clinical results for a personalized messenger RNA cancer vaccine developed by Moderna and Merck are...
A Third Arm for Therapists: The Surgeon Bringing ‘Self-Driving’ Tech to Physical Rehab
Artificial intelligence may be able to detect a patient’s disease, but it cannot move stiff arms and legs for them.
VOYXACT Preserves Kidney Function for Two Years in Phase 3 IgA Nephropathy Trial
Otsuka Pharmaceutical’s VOYXACT (active ingredient: sibeprenlimab) demonstrated long-term kidney protection by...
Alteogen Signs $365 Million Licensing Deal for Subcutaneous Drug Delivery Platform ALT-B4
Biotechnology firm Alteogen has signed an exclusive technology-transfer agreement worth up to $365 million...
From Retinal Scans to Brain Imaging: South Korea Backs Six Medical AI Tools for Fast-Track Hospital Adoption
Medical AI tools designed to assess cardiovascular risk from retinal images and analyze brain scans for stroke severity...
HK inno.N's K-CAB Secures Sixth Indication to Prevent Ulcers from Long-Term NSAID Use
HK inno.N’s gastroesophageal reflux disease drug K-CAB has expanded its approved uses to include the prevention of...
Forget Wegovy and Mounjaro: How Hanmi’s 'EPPE' Is Redefining Obesity Care
Hanmi Pharmaceutical has officially named its in-development obesity treatment "EPPE.